• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Dr. George Talks About New Data on Checkpoint Inhibitors

Article

In this video, Daniel George, MD, Director, Prostate Clinic, Genitourinary Oncology, Duke Cancer Institute, shares his thoughts on the most exciting data to be presented on immunotherapies at the ASCO Annual Meeting 2013.

In this video, Daniel George, MD, Director, Prostate Clinic, Genitourinary Oncology, Duke Cancer Institute, shares his thoughts on the most exciting data to be presented on immunotherapies at the ASCO Annual Meeting 2013. A number of abstracts will be presented on both single agent and combinations of checkpoint inhibitors. Specifically, there is a Phase I study from Memorial Sloan-Kettering and Yale demonstrating a depth of response with the combination of ipilimumab and nivolumab for the treatment of melanoma. Dr George notes that this trial demonstrates "just how robust immunotherapy can be."

This video was taken on June 1, 2013, at the ASCO Annual Meeting 2013 in Chicago, IL.

Related Videos
Andrew Evens, DO, MBA, MSc, deputy director for clinical services and chief physician officer, Rutgers Cancer Institute
Ivo Carre, PhD, senior business analyst, Lifescience Dynamics
Drs Yelena Janjigian and Zev Wainberg | Background image credit: ipopba - stock.adobe.com
Nicoletta Colombo, MD, PhD
AHA 2025 recap layered on photo of Bourbon Street in New Orleans | Image credit: SeanPavonePhoto - stock.adobe.com
Screenshot of an interview with Stephen Nicholls, MBBS, PhD
Screenshot of an interview with Roy Mathew, MD
Screenshot of an interview with Vallerie McLaughlin, MD
Related Content
© 2025 MJH Life Sciences
AJMC®
All rights reserved.